Axol Bioscience Acquires Phenocell

ABL Diagnostics Selected by Évry Commercial Court to Acquire TEXCELL’s Operations

July 24, 2026

Healthcare Services

ABL Diagnostics said it has been selected by the Évry Commercial Court to acquire the assets and business operations of TEXCELL. The deal involves the transfer of 29 employees and the continuation of TEXCELL’s operations at the Genopole site in Évry-Courcouronnes, strengthening ABL Diagnostics’ virology and biosafety capabilities for biopharmaceutical customers.

InSphero AG Acquires PhenoVista Biosciences, Inc.

May 20, 2026

Healthcare Services

InSphero AG announced it has acquired PhenoVista Biosciences, Inc., a San Diego-based contract research organization specializing in high-content imaging and phenotypic assay technologies. The deal is intended to expand InSphero’s advanced 3D, cell-based assay and imaging capabilities and accelerate adoption of more predictive, human-relevant drug discovery and toxicology workflows.

Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business

February 23, 2026

Biotechnology

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.

Lonza AG Acquires PharmaCell BV

June 1, 2017

Biotechnology

Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.

Nicox S.A. Acquires Aciex Therapeutics, Inc.

July 2, 2014

Pharmaceuticals

Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.